<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981068</url>
  </required_header>
  <id_info>
    <org_study_id>Dahanca 37</org_study_id>
    <nct_id>NCT03981068</nct_id>
  </id_info>
  <brief_title>DAHANCA 37. Re-irradiation With Proton Radiotherapy</brief_title>
  <official_title>DAHANCA 37 A Phase II Study of Intensity Modulated Proton Therapy (IMPT) for Re-irradiation With Curative Intent for Recurrent or New Primary Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Head and Neck Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Head and Neck Cancer Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Summary Design Phase II observational&#xD;
&#xD;
      Treatment&#xD;
&#xD;
        -  60 Gy/50 fx / 10W-1 at 1.2 Gy/fx&#xD;
&#xD;
           o i.e. EQD2 tumor=56 Gy, EQD2 late=50.4 Gy at α/β= 10 and 3, respectively&#xD;
&#xD;
        -  Proton radiotherapy&#xD;
&#xD;
        -  Concomitant cisplatin for eligible patients*&#xD;
&#xD;
        -  Nimorazole recommended for SCC* *The concurrent medical treatment (weekly cisplatin and&#xD;
           nimorazole) are prescribed according to the national treatment guidelines, and are not&#xD;
           part of the experimental treatment.&#xD;
&#xD;
      Endpoints&#xD;
&#xD;
        -  Primary:&#xD;
&#xD;
           o Any new late toxicity grade &gt;=3 according to CTC AE 5.0&#xD;
&#xD;
        -  Secondary&#xD;
&#xD;
             -  Side effects according to DAHANCA scoring system&#xD;
&#xD;
             -  Quality of life and PROM according to EORTC C30 and HN43&#xD;
&#xD;
             -  Loco-regional control (LRC)&#xD;
&#xD;
             -  Overall survival (OS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary Design Phase II observational Inclusion criteria&#xD;
&#xD;
        -  Histological verified loco-regional recurrence or new primary&#xD;
&#xD;
        -  Available dose plan from primary radiotherapy course&#xD;
&#xD;
        -  Comparative dose plan with advantages for proton radiotherapy e.g. integral dose&#xD;
&#xD;
        -  Dmax dose (0.03 cm3) on the cumulated photon dose plan≥90 Gy&#xD;
&#xD;
        -  Complete Response (CR)* after initial therapy, except in the case where the recurrence&#xD;
           is considered a geometric miss (recurrence center of mass (COM) outside the 95% of&#xD;
           prescription dose.&#xD;
&#xD;
        -  Inoperable or salvage surgery with R1/R2 resection, extranodal extension (ENE) or&#xD;
           extensive soft tissue infiltration&#xD;
&#xD;
        -  Absence of distant metastasis at both&#xD;
&#xD;
             -  clinical examination AND&#xD;
&#xD;
             -  PET-CT or CT of thorax and upper abdomen&#xD;
&#xD;
        -  Life expectancy due to age and co-morbidity of &gt;=1 year. The general condition must be&#xD;
           sufficient to tolerate persistent significant side effects, e.g. tube or cannulae&#xD;
&#xD;
        -  PS&lt;=2 (WHO See appendix)&#xD;
&#xD;
        -  The patients should be able to read Danish in order to participate with quality of life&#xD;
           questionnaires, but can participate in the rest of the protocol without being fluent in&#xD;
           Danish, if capable of reading the patient information.&#xD;
&#xD;
           * Complete Response is defined as the situation when a trained clinician, ideally at a&#xD;
           multidisciplinary team conference, defines the patient as in complete remission, based&#xD;
           on clinical examination and available imaging. This status can of course later be&#xD;
           considered wrong as new information becomes available (sub-centimeter nodes grow etc.)&#xD;
           Exclusion criteria&#xD;
&#xD;
        -  Radical surgery (R0) and absence of adverse prognostic pathological features&#xD;
&#xD;
        -  Lymphoma or malignant melanoma&#xD;
&#xD;
        -  Inability to attend full course of radiotherapy or follow-up visits in the outpatient&#xD;
           clinic&#xD;
&#xD;
        -  As of 2019, patients with tracheal cannulas are excluded due to dose uncertainties. This&#xD;
           may change if a technical solution becomes available.&#xD;
&#xD;
      Treatment&#xD;
&#xD;
        -  60 Gy/50 fx / 10W-1 at 1.2 Gy/fx&#xD;
&#xD;
           o i.e. EQD2 tumor=56 Gy, EQD2 late=50.4 Gy at α/β= 10 and 3, respectively&#xD;
&#xD;
        -  Proton radiotherapy&#xD;
&#xD;
        -  Concomitant cisplatin for eligible patients*&#xD;
&#xD;
        -  Nimorazole recommended for SCC* *The concurrent medical treatment (weekly cisplatin and&#xD;
           nimorazole) are prescribed according to the national treatment guidelines, and are not&#xD;
           part of the experimental treatment.&#xD;
&#xD;
      Endpoints&#xD;
&#xD;
        -  Primary:&#xD;
&#xD;
           o Any new late toxicity grade &gt;=3 according to CTC AE 5.0&#xD;
&#xD;
        -  Secondary&#xD;
&#xD;
             -  Side effects according to DAHANCA scoring system&#xD;
&#xD;
             -  Quality of life and PROM according to EORTC C30 and HN43&#xD;
&#xD;
             -  Loco-regional control (LRC)&#xD;
&#xD;
             -  Overall survival (OS)&#xD;
&#xD;
      Derived projects&#xD;
&#xD;
        -  Morbidity (NTCP) modeling for cumulative doses&#xD;
&#xD;
        -  Metrics for uncertainties regarding cumulative doses&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any new grade &gt;=3 toxicity</measure>
    <time_frame>3 years after radiotherapy</time_frame>
    <description>CTC AE 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects, any grade</measure>
    <time_frame>5 years after radiotherapy</time_frame>
    <description>According to CTC AE or Dahanca</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and PROM</measure>
    <time_frame>6 months</time_frame>
    <description>EORTC QLQ HN43 , swallowing scale. Difference (mean) between baseline and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional control (LRC)</measure>
    <time_frame>5 years after radiotherapy -actuarial analysis</time_frame>
    <description>Abscence of locoregional failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Median Survival up to 5 years</time_frame>
    <description>Abscence of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Re-Irradiation with protons</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 Gy in 50 fraktions, 10 weekly with protons</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Re-irradiation</intervention_name>
    <description>Cisplatin for all eligible patients, nimorazole for all SCC</description>
    <arm_group_label>Re-Irradiation with protons</arm_group_label>
    <other_name>cisplatin</other_name>
    <other_name>nimorazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological verified loco-regional recurrence or new primary&#xD;
&#xD;
          -  Available dose plan from primary radiotherapy course&#xD;
&#xD;
          -  Comparative dose plan with advantages for proton radiotherapy e.g. integral dose&#xD;
&#xD;
          -  Dmax dose (0.03 cm3) on the cumulated photon dose plan≥90 Gy&#xD;
&#xD;
          -  Complete Response (CR)* after initial therapy, except in the case where the recurrence&#xD;
             is considered a geometric miss (recurrence center of mass (COM) outside the 95% of&#xD;
             prescription dose.&#xD;
&#xD;
          -  Inoperable or salvage surgery with R1/R2 resection, extranodal extension (ENE) or&#xD;
             extensive soft tissue infiltration&#xD;
&#xD;
          -  Absence of distant metastasis at both&#xD;
&#xD;
               -  clinical examination AND&#xD;
&#xD;
               -  PET-CT or CT of thorax and upper abdomen&#xD;
&#xD;
          -  Life expectancy due to age and co-morbidity of &gt;=1 year. The general condition must be&#xD;
             sufficient to tolerate persistent significant side effects, e.g. tube or cannulae&#xD;
&#xD;
          -  PS&lt;=2 (WHO See appendix)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radical surgery (R0) and absence of adverse prognostic pathological features&#xD;
&#xD;
          -  Lymphoma or malignant melanoma&#xD;
&#xD;
          -  Inability to attend full course of radiotherapy or follow-up visits in the outpatient&#xD;
             clinic&#xD;
&#xD;
          -  As of 2019, patients with tracheal cannulas are excluded due to dose uncertainties.&#xD;
             This may change if a technical solution becomes available.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Jensen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Centre for Particle Therapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth Jensen, PhD</last_name>
    <phone>+45 21284108</phone>
    <email>kennjens@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesper Eriksen, Professor</last_name>
    <email>jesper@oncology.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danish Center for Particle Therapy</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Jensen, Ph.D.</last_name>
      <phone>78450000</phone>
      <phone_ext>45</phone_ext>
      <email>kennjens@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Dorte Winther, Nurse</last_name>
      <phone>78450000</phone>
      <email>dorte.skriver.winther@auh.rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent</keyword>
  <keyword>reirradiation</keyword>
  <keyword>second primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimorazole</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

